Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Fesoterodin, ATC G04BD11 für die Zeit 01.08.2026 - 31.07.2028 (zzgl. Verlängerungsoption 1x12 Monate)

Section 130a Paragraph 8 SGB V allows health insurance companies and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurance. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly carries out substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB. For the medicines to be specified by the bidder in more detail in Annex 2 to the contract for the aforementioned substance Fesoterodin, ATC G04BD11, the DAK-Gesundheit intends to conclude medicine rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine rebate contracts. A rebate contract under the approval model for the aforementioned substance comes into force for the first time on 01.08.2026 and ends on 31.07.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.